Addex Therapeutics Ltd. (ADXN) stock
ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.50−0.33 (-8.62%)
Close on Nov 17, 2026Market cap $71.86KP/E –Yield –
Addex Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.06 CHF, down 185.7% from the year before. The highest annual figure on record is 0.07 CHF in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.06 CHF | -185.7% |
| FY2024 | Dec 31, 2024 | 0.07 CHF | – |
| FY2023 | Dec 31, 2023 | -0.14 CHF | – |
| FY2022 | Dec 31, 2022 | -0.46 CHF | – |
| FY2021 | Dec 31, 2021 | -0.45 CHF | – |
| FY2020 | Dec 31, 2020 | -0.48 CHF | – |
| FY2019 | Dec 31, 2019 | -0.56 CHF | – |
| FY2018 | Dec 31, 2018 | -0.07 CHF | – |
| FY2017 | Dec 31, 2017 | -0.25 CHF | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.01 CHF | – |
| Q2 FY2025 | Jun 30, 2025 | -0.02 CHF | – |
| Q2 FY2024 | Jun 30, 2024 | 0.13 CHF | – |
| Q2 FY2023 | Jun 30, 2023 | -0.04 CHF | – |
| Q2 FY2022 | Jun 30, 2022 | -0.19 CHF | – |
| Q2 FY2021 | Jun 30, 2021 | -0.14 CHF | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?